ALBI Grade Analyses of TACE Combined with Anti-Angiogenesis Therapies Plus PD-1 Inhibitors versus Anti-Angiogenesis Therapies Plus PD-1 Inhibitors in Advanced HCC DOI Creative Commons

Xin Hong,

Di Hu, Wen‐Jie Zhou

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 2505 - 2514

Published: Dec. 1, 2024

To evaluate the baseline albumin-bilirubin (ALBI) grade's role in advanced hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) plus anti-angiogenesis therapies and PD-1 inhibitors (TACE+TP) versus (TP). This multicenter retrospective study enrolled HCC undergoing TACE+TP or TP from January 2019 to June 2023 at three hospitals China. The primary outcomes were time progression of ALBI grade change score between initial final assessment point available, secondary consisted overall survival (OS) as well progression-free (PFS). One hundred eighty-three patients ultimately this for analysis, whom 44 categorized having an 1 (TACE+TP, n = 23; TP, 21) 139 classified 2 (n 77; 62). Time grade, indicating liver function deterioration, was comparable groups (median, 11.2 vs 19.3 months; P 0.353). Change available among two (difference least squares mean, 0.084). Irrespective group exhibited a significant enhancement OS displayed promising trend towards better PFS. had no negative influence on enhanced regardless when compared patients.

Language: Английский

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial DOI Creative Commons

Xiaoyang Hong,

Yongjian Guo,

Wenbo Shi

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 5, 2025

Language: Английский

Citations

1
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives DOI Creative Commons
Yuhang Chen,

Shengyuan Dai,

Chien‐shan Cheng

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Dec. 21, 2024

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its primary mechanism action involves inhibiting signal pathways such as vascular endothelial growth factor receptors (VEGFR) and fibroblast (FGFR), thereby reducing tumor cell proliferation angiogenesis affecting tumor's immune microenvironment. In liver cancer, although lenvatinib monotherapy has shown good clinical effect, problem drug resistance becoming more serious. This may be caused by variety factors, including genetic mutations, signaling pathway remodeling, changes order to overcome resistance, combination other therapeutic strategies gradually become research hotspot, it worth noting that checkpoint inhibitors (ICIs) application prospect. not only enhances anti-tumor response but also helps improve efficacy. However, therapy faces challenges regarding safety tolerability. Therefore, studying mechanisms identifying relevant biomarkers particularly important, aids early diagnosis personalized treatment. article reviews treating efficacy its with inhibitors, causes exploration biomarkers, novel for lenvatinib. We hope provide insights into use scientific settings, offering new cancer.

Language: Английский

Citations

4
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy DOI

Fei-Yu Zhao,

Xiaoming Zhang,

Niansong Qian

et al.

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(10)

Published: Feb. 26, 2025

In their study, Han et al compared the efficacy of bevacizumab plus sindilizumab interventional therapy with that lenvatinib for patients intermediate and advanced hepatocellular carcinoma. The triple therapy, which integrates targeted immunotherapy, has emerged as a promising research focus in treatment liver cancer. Consequently, it is utmost significance to select an appropriate combination immunotherapy suffering from

Language: Английский

Citations

0
A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor DOI Creative Commons

Saifeng Li,

Qin Wen, Wen-wu Huang

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 13, 2025

Abstract Purpose The incidence and mortality of hepatocellular carcinoma are still high according to National Cancer Center China. Atezolizumab plus bevacizumab has become one the standard regimens for first-line treatment unresectable carcinoma. However, some patients use lenvatinib in combination with immunotherapy instead a “atezolizumab-bevacizumab” regimen as lower risk bleeding esophagogastric varices. there is no evidence second-line therapy after progression on combined PD-1 inhibitor till now. Herein, we aim investigate among these patients. Patients methods Thirty-three varices were admitted Second Affiliated Hospital Nanchang University from January 2019 December 2023. They treated first line. efficacy was conducted RECIST1.1 criteria. endpoints included objective response rate (ORR), disease control (DCR), median overall survival (OS), free (PFS). Results We identified total 225 who received inhibitor, whom 33 (14.7%) therapy. 21 (63.6%) regorafenib 6 (18.2%) apatinib 4 (12.1%) remaining 2 or sorafenib monotherapy, respectively. Of patients, (6.1%) evaluated partial (PR), 16 (48.5%) had stable (SD), 15 (45.4%) experienced (PD). ORR 6.1%, DCR 54.6%. Median PFS 4.5 months, OS 7.2 12-month 27.3%. Overall follow-up done 37 without second line whose baseline levels matched those group. months group versus 3.0 ( p = 0.04). As different treatments line, 9.5%, 47.6%, 4.2 5.9 months. None got PR, 83.3%, 8.7 9.1 25.0%, 2.2 6.0 Conclusion effective. Regorafenib might be preferred options.

Language: Английский

Citations

0
Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies DOI Open Access
Yusra Zarlashat, Hafiz Salman Mushtaq, Linh Pham

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 6830 - 6830

Published: June 21, 2024

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and a significant global health burden, with increasing incidence rates limited treatment options. Immunotherapy has become promising approach due to its ability affect immune microenvironment promote antitumor responses. The performs an essential role in both progression development of HCC, different characteristics based on specific cells etiological factors. Immune checkpoint inhibitors, including programmed death-1/programmed death-ligand 1 inhibitors (pembrolizumab, nivolumab, durvalumab) cytotoxic T lymphocyte antigen-4 (tremelimumab ipilimumab), have potential treat advanced HCC overcome adverse effects, such as liver failure chemoresistance. Phase II phase III clinical trials highlight efficacy pembrolizumab respectively, patients, demonstrated by their positive effects overall survival progression-free survival. Tremelimumab exhibited modest response rates, though it does possess antiviral activity. Thus, still being investigated ongoing trials. Combination therapies multiple drugs benefits terms tumor improving patient outcomes compared monotherapy, especially for advanced-stage HCC. This review addresses immunotherapies early-, intermediate-, Additionally, highlights how combination therapy can significantly enhance survival, objective rate where options are limited.

Language: Английский

Citations

2
Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma DOI Creative Commons
Tong Liu,

Guorui Meng,

Shihui Ma

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 9, 2024

Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset insidious, and patients have no obvious discomfort in early stage, so it found late, opportunity for surgical radical treatment lost, resulting a poor prognosis. With introduction of molecular-targeted drugs represented by sorafenib, with middle- late-stage cancer regained light day. However, their therapeutic efficacy relatively low due to limited target drug action, toxic side effects, other reasons. At this time, emergence immunotherapy immune checkpoint inhibitors (ICIs) well breaks embarrassing situation, which mainly achieves anti-tumor purpose improving tumor microenvironment. Currently, ICI monotherapy, as combination therapy, has been widely used clinic, further prolonging survival advanced carcinoma. This article reviews development monotherapy therapy ICIs latest research progress.

Language: Английский

Citations

2
Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma DOI Open Access
Feng Han, Xiaohan Wang,

Chenzhou Xu

et al.

World Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 16(7), P. 3308 - 3320

Published: July 11, 2024

Combination therapy has emerged as the focus of research for unresectable hepatocellular carcinoma (HCC). In recent years, several studies have explored clinical efficacy and safety combination therapies transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) immune checkpoint (ICIs).

Language: Английский

Citations

0
Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era DOI Creative Commons
Ugo Testa

Expert Review of Molecular Diagnostics, Journal Year: 2024, Volume and Issue: 24(9), P. 803 - 827

Published: Aug. 28, 2024

Primary liver cancer is a major health problem being the sixth most frequent in world and third cause of cancer-related death world. The common histological type hepatocellular carcinoma (HCC, 75-80%).

Language: Английский

Citations

0
ALBI Grade Analyses of TACE Combined with Anti-Angiogenesis Therapies Plus PD-1 Inhibitors versus Anti-Angiogenesis Therapies Plus PD-1 Inhibitors in Advanced HCC DOI Creative Commons

Xin Hong,

Di Hu, Wen‐Jie Zhou

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 2505 - 2514

Published: Dec. 1, 2024

To evaluate the baseline albumin-bilirubin (ALBI) grade's role in advanced hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) plus anti-angiogenesis therapies and PD-1 inhibitors (TACE+TP) versus (TP). This multicenter retrospective study enrolled HCC undergoing TACE+TP or TP from January 2019 to June 2023 at three hospitals China. The primary outcomes were time progression of ALBI grade change score between initial final assessment point available, secondary consisted overall survival (OS) as well progression-free (PFS). One hundred eighty-three patients ultimately this for analysis, whom 44 categorized having an 1 (TACE+TP, n = 23; TP, 21) 139 classified 2 (n 77; 62). Time grade, indicating liver function deterioration, was comparable groups (median, 11.2 vs 19.3 months; P 0.353). Change available among two (difference least squares mean, 0.084). Irrespective group exhibited a significant enhancement OS displayed promising trend towards better PFS. had no negative influence on enhanced regardless when compared patients.

Language: Английский

Citations

0